Primary vs Secondary Hypogonadism: The Definitive Guide

What is the difference between primary and secondary hypogonadism?

Primary and secondary hypogonadism are the two main types of low testosterone, named for where the fault lies. In primary hypogonadism the testes themselves fail, so the pituitary's LH and FSH run high. In secondary hypogonadism the brain and pituitary send too little signal, so LH and FSH are low or normal. The type decides which causes to look for and which treatments can work. [1]

Testosterone is made in a relay. The hypothalamus, at the base of the brain, sends GnRH to the pituitary gland. The pituitary answers with two hormones. LH tells the Leydig cells in the testes to make testosterone, and FSH drives sperm production. Rising testosterone turns the signal down, like a thermostat. The low testosterone guide explains the relay in more detail. [1]

Doctors use a few more terms alongside the two main types:

• Primary (hypergonadotropic): low testosterone with high LH and FSH, and usually impaired sperm production. [1]
• Secondary (hypogonadotropic): low testosterone with LH and FSH that are low or "inappropriately normal". That means inside the lab range, but not raised the way they should be when testosterone is low. [1]
• Mixed: both levels affected, so LH and FSH can be anywhere. Causes include sickle cell disease, iron overload, thalassemia, steroid medicines and alcoholism, and a combined pattern is common in older men. [12], [13]
• Compensated: normal testosterone with a high LH, a pattern to watch rather than a diagnosis (see compensated hypogonadism). [4], [14]

A second sorting cuts across the first. Organic hypogonadism comes from permanent damage or a genetic cause, such as Klinefelter syndrome or pituitary surgery. Functional hypogonadism is a suppression that may reverse when its cause is treated, such as obesity, opioids or serious illness, and it usually has a secondary or mixed pattern. [1], [4], [15]

How is primary vs secondary hypogonadism diagnosed?

In two steps. First, low testosterone is confirmed the same way for both types: symptoms plus low results on at least two early-morning tests. Then LH and FSH show the type. The type decides the next tests: prolactin, iron and sometimes a pituitary scan for secondary, and a chromosome test for unexplained primary. [1], [3], [4], [16]

Which clues point to a type or a cause?

The symptoms of low testosterone are the same in both types, and sexual symptoms are the most specific. In the European Male Ageing Study (EMAS), they were more common with both the primary and the secondary pattern. The low testosterone guide covers symptoms in depth. Some clues point further: [2]

• Very small testes (under 6 mL) point toward primary hypogonadism and Klinefelter syndrome. [1]
• Puberty that never fully happened, with or without a poor sense of smell, points toward congenital hypogonadotropic hypogonadism (Kallmann syndrome when smell is affected). [17]
• Breast growth (gynecomastia), low sex drive, erectile dysfunction, infertility or a milky nipple discharge with a secondary pattern should prompt a prolactin test, says the Pituitary Society. [18]
• New headaches or vision changes can mean a pituitary growth and are a reason for a scan. [1]
• History: opioids, steroid tablets, past anabolic steroids, cancer treatment, mumps after puberty or undescended testes. [1], [4]

How low is low?

Each major guideline's testosterone line applies to both types; none sets a different number for primary and secondary. Checked September 2026.

[3], [1], [19], [20], [4], [21], [12], [13], [22], [23], [15]

Every body wants symptoms plus at least two low morning results. The line falls between 264 ng/dL and about 350 ng/dL, depending on the body and the lab method. The type is then decided by LH and FSH, not by the testosterone number. The testosterone unit converter switches between ng/dL and nmol/L. [3], [1], [4]

How do doctors tell primary from secondary?

With LH and FSH, then tests that depend on the pattern:

[1], [3], [4], [9], [20], [12], [23], [15], [22]

All of them use LH, and usually FSH, to split the types, check prolactin for a secondary pattern and chromosomes for unexplained primary. They differ on when to scan the pituitary. A result below 150 ng/dL (5.2 nmol/L) with an LH that is not raised is the scan line for the AUA, the Endocrine Society and the BSSM. The VA refers men below that line to an endocrinologist. The EAU and EAA use a slightly higher line of 6 nmol/L (about 175 ng/dL). High prolactin, other pituitary problems and mass symptoms are triggers in most of them. [3], [1], [12], [20], [4], [15]

Doserly

From two low results to a type and a cause

1. 1. Symptoms + two low early-morning testosterone results

   Confirmed the same way for both types.

2. 2. Measure LH and FSH

   Before any testosterone or fertility medicine; not during acute illness or short-term opioid use; stop biotin 72 hours before.

LH and FSH high: primary pattern

• Chromosome test (karyotype) if there is no clear cause, especially with testes under 6 mL
• Karyotype and a Y-chromosome test with a sperm count under 5 million/mL or no sperm (AUA)
• Semen analysis if fertility matters, before any testosterone

LH and FSH low or normal: secondary pattern

• Prolactin (repeat a mildly high result; check medicines and macroprolactin)
• Iron saturation or ferritin
• Other pituitary hormones if suspected
• Review opioids, steroid tablets, weight, sleep and illness

Pituitary MRI when

• Below 150 ng/dL (5.2 nmol/L) with low or normal LH: Endocrine Society, AUA and BSSM scan; the VA refers to a specialist
• Below 6 nmol/L (about 175 ng/dL): EAU (weak) and EAA consider a scan
• Most guidelines: prolactin that stays high, other pituitary hormones affected, or headaches or vision changes

Compensated pattern: Normal testosterone with high LH: watched, not usually treated.

LH and FSH are measured before any treatment: testosterone and fertility medicines change them.

How do you read the LH and FSH pattern?

By comparing LH with testosterone drawn at the same time. High LH with low testosterone means the testes are not answering. Low LH with low testosterone means the signal is weak. The trap is a "normal" LH: a healthy pituitary should push LH up when testosterone is low, so an LH inside the lab range still counts as the secondary pattern. [1], [13]

[2], [8], [24]

These cut-offs are research definitions; no guideline sets its own LH number, so a result is read against the lab's range and the testosterone level. At an infertility clinic, men with the primary pattern had by far the highest odds of having no sperm (odds ratio 24.54). The AUA notes that a raised FSH with low testosterone typically means impaired sperm production. [24], [3]

Doserly

Four patterns of testosterone and LH

European Male Ageing Study: share of 3,369 men aged 40–79 in each pattern. Bars run from 0 to 12%.

Secondary: 11.8%

Testosterone low, LH low or normal. Brain or pituitary signal is weak; an ‘inappropriately normal’ LH counts here.

Primary: 2.0%

Testosterone low, LH high. The testes fail, so the pituitary pushes LH up.

Compensated: 9.5%

Testosterone normal, LH high. The testes keep up only with extra LH; watched, not usually treated.

Normal: no single figure

Testosterone normal, LH low or normal. No hypogonadism pattern. The rest of the men; the study summary gives no single figure for this group.

EMAS cut-offs: testosterone 10.5 nmol/L (about 303 ng/dL), LH 9.4 U/L. These are research definitions, not guideline thresholds. Mixed hypogonadism can sit anywhere on the LH axis.

What can throw the pattern off?

• Treatment already started. Outside testosterone switches off LH and FSH: in trials both fell on testosterone gel and rose on enclomiphene. An LH measured on treatment says nothing about the cause. [25]
• Illness. Testosterone fell below normal in 62% of acutely ill men in hospital, with both patterns appearing and then passing. The Endocrine Society advises against testing during acute illness or short-term opioid use. [26], [1]
• Biotin supplements can make LH and FSH read falsely high or low; stop them at least 72 hours before. [1]
• Recent anabolic steroids shut the signal down for months after stopping. [27]

When is a pituitary scan needed?

When testosterone is very low with a low or normal LH, prolactin stays high, other pituitary hormones are affected, or there are headaches or vision changes. Scans find something important mostly in those men. Among 164 men with erectile dysfunction and the secondary pattern, 11 (6.7%) had a potentially serious lesion. The larger ones were all in men at 104 ng/dL or less. In another 51 men, 3 of the 4 with a small tumor had prolactin more than twice the upper limit of normal. Only 1 of the 17 men with testosterone under 200 ng/dL had one. [3], [1], [28], [29]

A high prolactin is checked again first. The Pituitary Society advises three checks. Repeat a result under five times the upper limit of normal. Review medicines that raise prolactin, such as some antipsychotics. Test for macroprolactin, an inactive form that raises the reading without symptoms; it explained 6.28% of high results in men in one cohort. An underactive thyroid and kidney or liver failure can also raise prolactin mildly. [18], [30]

Which tests suit a primary pattern?

• A chromosome test (karyotype) when primary hypogonadism has no clear cause. The Endocrine Society stresses testes under 6 mL, and the VA says small testes. The AUA tests with a sperm count under 5 million/mL or no sperm, adding a Y-chromosome test. Among 1,663 infertile men with no sperm, a chromosome problem was found in 20.2% with a high FSH against 4.9% with a normal FSH. Klinefelter syndrome made up 83% of those in the high-FSH group. [1], [20], [3], [31]
• A semen analysis when fertility matters, before any testosterone. [32], [1]

What causes primary and secondary hypogonadism?

Primary hypogonadism comes from damage to the testes: genetic conditions, injury, infection, cancer treatment and age. Secondary hypogonadism comes from anything that quiets the brain's signal: pituitary disease, conditions present from birth and, far more often, obesity, opioids and other medicines. In EMAS, a body mass index (BMI) of 30 or more was strongly linked with the secondary pattern (relative risk ratio 8.74), while older age was linked mainly with the primary pattern (3.04). [1], [4], [2]

What damages the testes themselves?

• Klinefelter syndrome (an extra X chromosome, 47,XXY), the most common genetic cause. It affects about 153 in 100,000 males (about 1 in 650). Only about 1 in 4 adult men with it have been diagnosed, most of them as adults. Among 1,581 men with it who had testosterone measured in a large international records network, 70.4% were under 300 ng/dL. Only 59.0% of those were prescribed testosterone. [5], [33], [34]
• Undescended testes. About 1–2% of boys have a testicle still undescended after 3–4 months of age. In 6,376 young men, a history of it went with a 28% lower sperm concentration and a 6% lower testosterone-to-LH ratio, a sign of slightly weaker testes. [22], [35]
• Mumps orchitis. After puberty, mumps inflames the testes (orchitis) in about 25% of cases, two-thirds of them on one side. Fertility is kept in about 75%. When both sides are affected, sperm production recovers in only about a third. How often it lowers testosterone is not known. [22]
• Cancer treatment. After testicular cancer, 11% of men treated with surgery alone had low testosterone and 41% a raised FSH; after chemotherapy plus radiotherapy, 37% had low testosterone. In survivors followed for decades it rose from 12% to 41%, against 5% to 11% in similar men without cancer. Among 143 long-term lymphoma survivors, 15% had low calculated free testosterone, more often after intensive Hodgkin lymphoma treatment. [6], [36], [37]
• Varicocele (enlarged veins around a testicle). Testosterone was about 82 ng/dL higher after repair in pooled studies, and about 114 ng/dL higher in men who were low beforehand. These were mostly before-and-after comparisons without an untreated group. Whether a varicocele causes low testosterone is still debated (low testosterone guide). [38], [39], [40]
• Other causes: injury or twisting (torsion), removal of the testes, testes absent from birth, myotonic dystrophy, HIV, some chemotherapy and radiation, the antifungal ketoconazole, alcohol-related liver disease, spinal cord injury and older age. [1], [4], [2]

What switches off the brain's signal?

• Prolactin-making tumors (prolactinomas). Too much prolactin switches off the brain's signal. In men most prolactinomas are large (about 4 large to every small one). The Pituitary Society says large ones in men are more aggressive and respond less often to medicine. [18]
• Other pituitary and hypothalamic disease: other tumors, pituitary surgery or radiation, head injury, bleeding into the pituitary and inflammation. These can affect thyroid and cortisol signals too, which is why other pituitary hormones are tested. [1], [22]
• Conditions present from birth. Congenital hypogonadotropic hypogonadism affects about 1 in 4,000 to 10,000 males. More than 25 genes are linked to it, and about half of those affected have a poor or missing sense of smell. [22], [17]
• Iron overload (hemochromatosis). In 141 men with the inherited form, 9 (6.4%) had low testosterone with low LH and FSH, and 8 of them had liver cirrhosis. [41]
• Steroid tablets. Testosterone was 33% lower on long-term prednisolone tablets, but not significantly lower with inhaled steroids. [42]
• Obesity and type 2 diabetes, the most common drivers in middle-aged men. In EMAS, new secondary hypogonadism appeared in 155.9 per 10,000 men a year, driven by obesity and weight gain. In another study, a third of men with type 2 diabetes had low free testosterone with lower LH and FSH. See obesity-related hypogonadism. [8], [43]
• Anabolic steroids, after stopping. About 2.5 years later, 27% of former users still had testosterone below 12.1 nmol/L. See TRT vs steroids. [44]
• Serious illness, severe dieting and heavy training, usually reversibly. [1], [22]

Do not stop a prescribed medicine on your own to test this: steroid tablets and opioids need a supervised plan.

Opioid-induced androgen deficiency: how do opioids lower testosterone?

Opioid painkillers and opioid treatment medicines such as methadone suppress the brain's signal to the testes, a secondary hypogonadism called opioid-induced androgen deficiency (OPIAD). In pooled studies, 63% of men using opioids had low testosterone. It is common, often missed, and at least partly reversible when the dose falls. [7]

How it works. US opioid labels say opioids inhibit LH and stimulate prolactin. Since March 2016 the FDA has required every opioid label to warn that long-term use may cause androgen deficiency. The warning notes that a causal role has not been proven and says people with symptoms should have lab tests. Testosterone can fall by more than half within hours of a dose and usually returns 24–72 hours after a short course, or up to a month depending on the dose. [45], [46], [47]

How common. The pooled 63% comes from 15 studies and 3,250 patients. Reviews give 20–80% and 21–86%, because studies differ in opioid, dose, duration, age and definition. On average, testosterone was about 165 ng/dL lower in men using opioids. [7], [48], [47], [49]

Which opioids and doses matter.

• The Endocrine Society says nearly all opioids at doses equal to 30 mg of methadone a day suppress testosterone, and longer-acting ones more so. In men taking opioids daily, 57% on long-acting opioids were deficient against 35% on short-acting ones (odds ratio 3.39), and higher doses raised the odds. [1], [50], [51]
• Buprenorphine suppresses it less than methadone. In one study, men on buprenorphine averaged 5.1 ng/mL (17.7 nmol/L) against 2.8 ng/mL (9.7 nmol/L) on methadone. In another, 28% against 65% were under 12 nmol/L. Testicular failure was uncommon, and there was no link with the methadone dose. [52], [53]
• Spinal pumps and sustained-action tablets. With long-term intrathecal opioids (given by a pump into the fluid around the spinal cord), 25 of 29 men had testosterone under 9 nmol/L. With sustained-action oral opioids, total testosterone was low in 74%, and 39 of 45 men reported severe erectile dysfunction or low libido. [54], [55]
• Tramadol and kratom have thin evidence: one study in men dependent on very high tramadol doses (lower testosterone, higher prolactin) and one of 19 kratom users (no suppression found). [56], [57]

Often missed. Among US men on long-term opioids, only 17.15% had testosterone tested within 5 years and 9.44% were diagnosed. In a 20-year study of people with heroin dependence, none of those found to have hypogonadism had been diagnosed before. The AUA suggests considering a test in long-term opioid users even without symptoms. [58], [59], [3]

Does it recover? Often, when opioids fall. In 25 men tapering opioids after head and neck cancer, testosterone rose within a month. In the heroin-dependence study, hypogonadism affected 3.3% of those who became opioid-free against 26.7% of those still using. Changing an opioid is a decision for your prescriber, because stopping suddenly can bring withdrawal and pain. [60], [59]

What are compensated and mixed hypogonadism?

Compensated hypogonadism is normal testosterone with a high LH, found in 9.5% of EMAS men aged 40–79. It often returned to normal and was not clearly linked with androgen deficiency. But men with it were much more likely to develop primary hypogonadism later (odds ratio 15.97). The EAU calls its significance unclear. The UK Society for Endocrinology expects lifelong treatment for a confirmed diagnosis, but makes a possible exception for this pattern. [2], [14], [4], [22]

Australia's subsidy rules use a high LH as evidence of true deficiency. The rule covers men 40 and older without a known pituitary or testicular disorder. For them, testosterone of 6–15 nmol/L qualifies only with an LH more than 1.5 times the young-male upper limit or above 14 IU/L, whichever is higher. A known disorder qualifies through a specialist with no level stated. Checked September 2026. [61]

Mixed hypogonadism affects both the testes and the pituitary (see the types). [12]

How is primary vs secondary hypogonadism usually treated?

By type and cause. Primary hypogonadism is treated with testosterone, because failing testes cannot respond to anything else. Secondary hypogonadism is treated first by fixing the cause where possible, then with testosterone, or with medicines that restart the testes when children are wanted. This section describes the choices clinicians weigh; it is not a personal plan. [1], [4]

[4], [19], [18], [1], [9]

Why does the type change the treatment?

Because fertility medicines work by pushing the testes harder, and failing testes cannot respond. The EAU says SERMs such as clomiphene need a working hypothalamus–pituitary–testis chain, so they cannot work in primary hypogonadism or in secondary hypogonadism caused by organic damage. It also finds no substantial evidence that gonadotropins help in classic testicular failure. As the Endocrine Society puts it, gonadotropins can restore fertility in secondary hypogonadism but not in primary. [4], [9], [1]

How is primary hypogonadism treated?

With testosterone therapy, usually for life. When the testes have failed, stopping returns a man to his low starting point, and the UK Society for Endocrinology expects lifelong treatment. The type does not change the dose. The forms each have a guide (cypionate, enanthate, undecanoate injection, gel, oral capsules, nasal gel, pellets). The TRT dosage guide covers labeled doses and the TRT dose calculator turns a dose into mL and syringe units. Testosterone for women uses different products and doses; see testosterone therapy for women. [1], [22]

Fertility comes first if children are wanted. US labels warn that testosterone suppresses sperm production and that reduced fertility may not be reversible. Men who may want children can bank sperm before starting if they have any. For men with none, the options are surgical sperm retrieval for IVF with a single sperm injected into each egg (ICSI), donor sperm or adoption. [16], [1]

Klinefelter syndrome and fertility. Most men with it have no sperm in their semen, but surgery can still find some:

• Microsurgical retrieval (micro-TESE) finds sperm in about 50–60% of men with 47,XXY, according to the AUA and the American Society for Reproductive Medicine (ASRM). A meta-analysis found sperm in 44% of attempts, with pregnancy and live-birth rates of about 43% per ICSI cycle. [32], [62]
• Counted per man, results are lower: in one clinic, 14 of 138 men who started (10.1%) had their own biological child. [63]
• Retrieval rates were similar in adolescents (45%) and adults (42%), and hormone treatment beforehand raised testosterone without improving the chance of finding sperm. [64], [65]

How is secondary hypogonadism treated?

Cause first. The EAU strongly recommends losing weight, stopping medicines that interfere and treating other illnesses before starting testosterone. The Endocrine Society's 2026 statement calls weight loss typically first-line when obesity (a BMI over 27) is the only cause. How much testosterone comes back is in the research. [4], [19]

Prolactinoma. The Pituitary Society prefers cabergoline, a dopamine agonist that lowers prolactin and shrinks the tumor. US labels start cabergoline at 0.25 mg twice a week. The dose can rise by 0.25 mg twice a week, no sooner than every 4 weeks, up to 1 mg twice a week, until prolactin is normal. The labels ask for a heart-valve check (echocardiogram) before starting. Testosterone often recovers as prolactin falls. A level below 7.4 nmol/L (about 213 ng/dL) after 6 months predicted that it would stay low. The Society suggests considering testosterone when hypogonadism lasts more than 6 months on treatment, with caution for large tumors. For men who want children, it advises against testosterone and says hCG with FSH can be considered. [18], [66], [67]

Fertility: hCG, with FSH if needed. The EAU calls gonadotropins the standard for men with secondary hypogonadism who want to father children. hCG acts like LH to restart testosterone production in the testes. FSH is added when sperm production needs it. Both are FDA-approved for men with hypogonadotropic hypogonadism: hCG labels list regimens for hypogonadotropic hypogonadism, and an FSH (follitropin) label covers starting sperm production. The hCG guide covers doses. Checked September 2026. [4], [68], [69]

Tablets that raise LH and FSH (SERMs). Clomiphene and enclomiphene block estrogen's feedback in the brain, so they suit functional secondary hypogonadism with a working pituitary. The AUA says men with a low or low-normal LH are candidates. Clomiphene is approved only for women, and its label says no adequate studies show it works for male infertility. Enclomiphene is approved nowhere. The EU refused it in 2018 over unproven benefit and a blood-clot risk. In the US it is under evaluation for pharmacy compounding, which is not an approval. The Endocrine Society says clomiphene's benefits and safety have not been shown in randomized trials. Checked September 2026. [3], [70], [71], [72], [1]

Testosterone therapy is used when the cause cannot be fixed and fertility is not a near-term goal, as in pituitary damage or congenital hypogonadotropic hypogonadism. [1], [4]

How is opioid-related low testosterone treated?

The first question is whether the opioid can be reduced or changed; low testosterone is much less common with buprenorphine. The Endocrine Society suggests considering testosterone for men with sexual symptoms who are unlikely to stop opioids. The EAA says it may be withdrawn later if opioids can be stopped or swapped. [1], [15]

In two randomized trials, testosterone did not improve reported pain. In 84 men randomized to gel or placebo for 14 weeks (65 analyzed), it improved pain sensitivity on lab tests, sexual desire and body composition, but not self-reported pain. In 41 men given undecanoate injections or placebo for 24 weeks, lean mass rose 3.6 kg against 0.1 kg with no change in pain. Office systolic blood pressure rose 6.2 mm Hg on testosterone and fell 7.0 mm Hg on placebo, a 13.2 mm Hg difference. A records study of 27 men and a small open-label patch study were more positive, but neither had a fair comparison group. [73], [74], [75], [76], [77]

Is treatment lifelong?

• Primary, and organic secondary: usually. [22]
• Congenital hypogonadotropic hypogonadism: usually, but 10–20% of men recover. In one series, 5 of 50 men recovered after a pause in treatment. In the 15 men with recovery in that study, their own testosterone went from an average of 55 to 386 ng/dL. In a larger cohort of 308 patients (men and women), 44 recovered, an estimated lifetime chance of 22%, though 5 men later relapsed. [17], [78], [79]
• Functional secondary: sometimes not, after weight loss or opioid changes. [15]
• Iron overload: removing iron rarely brings testosterone back after age 40. [80]

After testosterone stops, LH and FSH return slowly: after two years of injections in the T4DM trial, they recovered gradually over 12 months. No study has measured recovery specifically in true secondary hypogonadism. See stopping TRT. [81]

What does the research show?

Most of the evidence on the types comes from population and clinic studies. Testosterone trials enrolled men by testosterone level and symptoms rather than by type, and trials of fertility-sparing tablets were small. [2], [82], [83], [84]

Does fixing the cause bring testosterone back?

Often in functional and prolactin-related secondary hypogonadism, rarely otherwise.

In a 2026 review, GLP-1 weight-loss medicines raised total testosterone in men with obesity or diabetes while keeping LH and FSH working. They are not approved for low testosterone (TRT with GLP-1 medicines). [90]

Does testosterone therapy help, whatever the type?

It helps sexual function most. In the Testosterone Trials, a year of gel in 790 men aged 65 and older improved sexual activity, desire and erections and slightly improved mood. It raised spine bone density (7.5% against 0.8% on placebo). It corrected anemia in 58.3% of men with unexplained anemia against 22.2% on placebo. It did not improve energy or walking. These trials did not report results by type; see the low testosterone guide. [83], [91], [92]

Do fertility-sparing tablets work in secondary hypogonadism?

They raise testosterone reliably; whether they relieve symptoms as well as testosterone is less clear.

• Levels. Clomiphene or enclomiphene raised total testosterone by about 274 ng/dL against placebo in randomized trials, similar to testosterone gel, while raising LH and FSH. [84]
• Symptoms. Clomiphene improved libido scores less than testosterone therapy in a 2026 meta-analysis. In the one placebo-controlled trial in men with secondary hypogonadism and erectile dysfunction, sexual function generally did not improve. [93], [94]
• Sperm. In two trials in overweight men, enclomiphene kept sperm concentration normal over 16 weeks while testosterone gel markedly reduced it. [25]
• Long-term use. Among men treated with clomiphene for more than 3 years, 88% had normal testosterone and 8% reported side effects such as mood changes, blurred vision or breast tenderness. [95]

No medicine is proven to restart failing testes, and there are no randomized trials of clomiphene or hCG in men with a high LH and FSH. [65], [9]

What are the risks of hypogonadism and of treating it?

Is untreated hypogonadism dangerous?

Low testosterone is linked with a higher risk of death in observational studies, without proof that it causes those deaths or that treatment prevents them. In EMAS, men with severe late-onset hypogonadism died at about 5 times the rate of other men over a median 4.3 years (hazard ratio 5.5). The type adds its own risks. Large prolactinomas in men can grow and need closer follow-up. Klinefelter syndrome carries a higher risk of metabolic disease, heart disease and blood clots. [96], [18], [9]

Is testosterone therapy safe?

In the largest trial, testosterone gel did not raise the risk of heart attack or stroke, but it did raise some other risks. TRAVERSE randomized 5,204 men aged 45–80 with low testosterone and heart disease or high heart risk to daily testosterone gel or placebo gel. Among the 2,596 men who used testosterone gel and the 2,602 who used placebo gel, it found: [82]

• Heart attack, stroke or death from heart disease: 182 of 2,596 men on testosterone (7.0%) against 190 of 2,602 on placebo (7.3%). The hazard ratio was 0.96, with a likely range of 0.78 to 1.17, which met the trial's safety margin of 1.5. [82]
• Heart rhythm: atrial fibrillation (an irregular heart rhythm) 3.5% against 2.4%, and nonfatal rhythm problems needing treatment 5.2% against 3.3%. [97]
• Kidneys and clots: acute kidney injury 2.3% against 1.5%, and pulmonary embolism (a clot in the lungs) 0.9% against 0.5%. [97]
• Fractures: 91 of 2,601 men on testosterone (3.50%) against 64 of 2,603 on placebo (2.46%), counting every randomized man (hazard ratio 1.43). Testosterone did not prevent fractures. [98]
• Prostate: high-grade prostate cancer in 5 of 2,596 men (0.19%) against 3 of 2,602 (0.12%), not a significant difference. Men with a PSA above 3.0 ng/mL were excluded. [99]
• Limits: it tested only a daily gel; men used it for an average of 21.7 months; about 61% stopped their study gel early; and it enrolled only men at high heart risk. [82], [97]

Doserly

TRAVERSE: absolute results

Testosterone gel (2,596 men)Placebo gel (2,602 men)

Heart attack, stroke or heart death

Testosterone 7.0% vs placebo 7.3% (182 vs 190 men; hazard ratio 0.96, 95% CI 0.78–1.17; met the 1.5 safety margin)

Nonfatal rhythm problems needing treatment

Testosterone 5.2% vs placebo 3.3%

Atrial fibrillation

Testosterone 3.5% vs placebo 2.4%

Clinical fracture

Testosterone 3.5% vs placebo 2.5% (91 of 2,601 vs 64 of 2,603 in the full analysis set)

Acute kidney injury

Testosterone 2.3% vs placebo 1.5%

Venous clots (all)

Testosterone 1.7% vs placebo 1.2%

Pulmonary embolism

Testosterone 0.9% vs placebo 0.5%

About 5,200 men aged 45–80 at high heart risk; daily gel; mean treatment 21.7 months; about 61% stopped their study gel. Not a trial of injections.

In February 2025 the FDA added the TRAVERSE results to all testosterone labels, removed boxed-warning language about a higher heart risk and required blood-pressure warnings. It kept the limitation for "age-related hypogonadism", which matters less for primary and organic secondary hypogonadism because they have a clear cause. In June 2026 the FDA asked makers to remove that limitation and narrow the prostate cancer contraindication; as of September 2026 those requests are not yet in any label. See TRT and heart health. [100], [101], [97]

Other risks on treatment: testosterone raises hematocrit and blood pressure. In the T4DM trial of injections, hematocrit went above 54% in 106 of 491 men on testosterone (22%) against 6 of 484 on placebo (1%); see hematocrit on TRT. Clomiphene's label notes reports of breast growth and testicular tumors in men. [102], [100], [70]

What if you want children?

• Both types: testosterone is the wrong choice while trying to conceive. The AUA says not to prescribe it to men trying to conceive, the AUA and ASRM extend that to men interested in future fertility, and the EAU and ICSM agree. [3], [32], [4], [21]
• Secondary: hCG, with FSH when needed, can start sperm production, and SERMs usually keep it going. [1], [25]
• Primary: fertility medicines do not help; the options are sperm banking before treatment, sperm retrieval for ICSI, donor sperm or adoption. [1], [9]
• After testosterone: in contraceptive studies of healthy men, sperm returned in 67% within 6 months and in all within 24 months. Recovery after years of therapy, or with testes already failing, may be slower or incomplete. [103], [16]

See TRT and fertility and hCG vs gonadorelin vs enclomiphene.

Who should be especially cautious?

• Men who may want children: testing the type and banking sperm come before any testosterone. [1], [3]
• Men with headaches, vision changes, or very low testosterone with a low LH, who need a pituitary work-up first. [1], [3]
• Men with Klinefelter syndrome starting testosterone, at higher risk of blood clots and diabetes, particularly when treatment starts. [9]
• Men on opioids, whose blood pressure rose on testosterone in a trial, and who should not change opioids on their own. [75]
• Men with a prolactinoma, because testosterone may affect large tumors. [18]
• Men with a high hematocrit, untreated severe sleep apnea, a recent heart attack or stroke, or prostate or breast cancer, whom the Endocrine Society advises against starting. [1]
• Drug-tested athletes (see legal status), under-18s (testosterone for delayed puberty belongs in specialist care) and women (see testosterone therapy for women). [104]

Which medicines interact or change the results?

• Opioids lower testosterone, and testosterone raised blood pressure in men on opioids. [75]
• Insulin and other diabetes medicines: US testosterone labels say testosterone may lower blood sugar, so their doses may need to come down. [105]
• Medicines that raise prolactin, such as some antipsychotics, can cause a secondary pattern. [18]
• Steroid tablets lower testosterone, and biotin distorts LH and FSH tests. [42], [1]

Bring a complete list, including supplements, to a pharmacist or prescriber. Checked September 2026.

Is testosterone legal, and is it allowed in sport?

Checked September 2026. Rules differ by country and change often.

• United States. Testosterone and its esters are Schedule III controlled substances, prescription only. [10]
• United Kingdom. Testosterone is a Class C controlled drug, in Schedule 4 Part II of the Misuse of Drugs Regulations. [106]
• Canada. Testosterone is a Schedule IV controlled substance. [107]
• Australia. Testosterone is a Schedule 4 prescription-only medicine with extra controls on possession. [108]
• Sport. The World Anti-Doping Agency (WADA) prohibits testosterone, hCG and SERMs at all times, and its 2027 list keeps them prohibited. It grants an exemption for testosterone or hCG only for hypogonadism with an organic cause. Functional low testosterone from ageing, obesity, overtraining or past anabolic steroid use does not qualify, and neither does a low free testosterone alone. [104], [11]

For access, cost and coverage, see the country guides for the United States, the United Kingdom, Canada, Australia and Europe.

What do people report about primary and secondary hypogonadism?

Most public posts on this topic come before any treatment: men with a low result, an LH and FSH result they cannot read, and conflicting advice. The threads below are recent public Reddit discussions, read with their replies; they show what people go through, not how often it happens.

What is it like to be told LH and FSH are "normal"?

Confusing, by many accounts. A man in his 30s documented five results between 200 and 283 ng/dL over seven years, with LH and FSH inside the lab range. Three endocrinologists declined to act. His thyroid test was also high, and he wanted fertility-sparing options. Another, in his 20s, had 248 ng/dL with LH and FSH inside the lab range, a borderline prolactin of 18.8 ng/mL and a clear pituitary scan. He was still waiting for an explanation. A third had years of low results, low LH and FSH, and thyroid disease untreated through puberty. He at first tested even lower after losing weight. A later retest came back at 21.89 nmol/L, against 6.89 before, with larger testes on ultrasound. [109], [110], [111]

Can the label change?

Yes. A man in his 20s who had over-exercised and under-eaten was first told he had primary hypogonadism and later, as he ate more, that his results showed a secondary pattern. Another, called primary by one clinician and borderline by a specialist, saw his levels rise over two years without treatment. A man in his 40s whose LH fell below 1 IU/L after five weeks on gel was told it could mean a pituitary cause. Replies pointed out that the gel itself suppresses LH. [112], [113], [114]

What do people with a primary pattern describe?

Fertility decisions come first for many. A man in his 30s saw his sperm count fall to zero, with an FSH of 47 and testosterone of 212 ng/dL. Before starting testosterone, he was waiting for his chromosome result, a sperm-freezing session and possibly micro-TESE. A testicular cancer survivor with results of 280–350 ng/dL noted that hCG was not an option for him because it is a tumor marker in his cancer follow-up. A man in his 20s at 23 ng/dL explained that he had had no testes since infancy, after some replies first suggested weight loss. A man with past mumps orchitis found that enclomiphene raised his testosterone for years without restoring his libido. [115], [116], [117], [118]

What do people with prolactin problems describe?

A wide range. One man's high prolactin turned out to be mostly macroprolactin. A man in his 30s with a large prolactinoma saw prolactin fall from over 200 to 55.8 ng/mL over more than a year of cabergoline, while testosterone stayed at 75 ng/dL. Another's prolactin normalized within 90 days while testosterone stayed in the low 100s, and his clinician added weekly testosterone. A man in his 20s with no tumor rose from 14.6 to 23.7 nmol/L on cabergoline but felt no different. [119], [120], [121], [122]

What do men on opioids describe?

Hard trade-offs. A man in his 20s relied on buprenorphine for severe pain and had results from 107 to 382 ng/dL. He weighed stopping it to learn his true level against staying on it and adding testosterone. A man on methadone measured 173 ng/dL at 1 pm and 348 ng/dL on a repeat drawn at noon, and worried the second result would end his referral. [123], [124]

What happened with fertility-sparing treatment?

Numbers often moved more than symptoms. On prescribed enclomiphene, a man in his 20s went from 327 to 991 ng/dL in 38 days, but his fatigue stayed and his sex drive fell. A man in his 30s on hCG alone for 13 months reported better energy and muscle but libido still far below his old level, and lowered the dose after his hematocrit rose. A man with absent puberty and undetectable LH and FSH felt no better on hCG over 8 weeks, then much better after starting testosterone. [125], [126], [127]

How can you judge a primary-or-secondary story?

Ask: Were LH and FSH measured before any testosterone, hCG or tablets, on a morning when the person was well? Was prolactin repeated, and macroprolactin checked? Were opioids, steroid tablets, past anabolic steroids, weight change, sleep or thyroid problems in the picture? For a primary pattern, were a chromosome test and a semen analysis done? And what did the next test show?

These selected discussions show what people experience and the questions research has not answered. They are not a survey of all men with hypogonadism, a success rate or a substitute for the studies above.

What should you track?

Before a diagnosis: each testosterone result with its date, time and fasting status, and the LH, FSH and prolactin results that go with it. After a diagnosis: what your clinician monitors for your type and treatment. Use this summary to prepare questions; it is not a personal testing plan. [1], [3]

[1], [3], [18], [100]

A single result is one point on a line. Illness, food, time of day and the lab method all move testosterone and LH. A series of morning results under similar conditions says more than any one number. The TRT blood work guide covers monitoring on treatment. [1], [26]

Common questions about primary and secondary hypogonadism

What does low testosterone with normal LH mean?

Usually a secondary pattern. When testosterone is low, a working pituitary should raise LH, so an LH inside the normal range is "inappropriately normal". The next steps are usually prolactin and iron tests and a review of medicines, weight and sleep. A pituitary scan follows if testosterone is very low or prolactin stays high. [1], [3] See reading the pattern.

What does high LH with low testosterone mean?

A primary pattern: the testes are not answering the signal. Guidelines suggest a chromosome test when there is no obvious cause, especially with small testes, and a semen analysis if fertility matters. High LH with normal testosterone is the compensated pattern, which is watched rather than treated. [1], [14] See tests for a primary pattern.

Can secondary hypogonadism be reversed?

Often, when the cause is functional or a prolactinoma. In EMAS, 42.9% of men with the secondary pattern returned to normal, more often after weight loss. Cabergoline restored testosterone in about half or more of men with a prolactinoma. Pituitary damage and congenital causes usually need lifelong treatment, although 10–20% of men with congenital hypogonadotropic hypogonadism recover. [8], [67], [17] See is treatment lifelong.

Can clomiphene or hCG treat primary hypogonadism?

No. Both work by making the testes work harder, and failing testes cannot respond. The EAU says SERMs cannot work in primary hypogonadism and finds no substantial evidence that gonadotropins help in testicular failure. [4], [9] See why the type changes treatment.

Do opioids like methadone or Suboxone lower testosterone?

Yes, most opioids do with long-term use: 63% of men using opioids had low testosterone in pooled studies. Buprenorphine, the main ingredient in Suboxone, suppresses it less than methadone: 28% against 65% had low testosterone in one study. Testosterone often recovers when opioids fall, but any change needs a supervised plan. [7], [53], [59] See opioids.

Can you have children with primary hypogonadism?

Sometimes, with help. Sperm can be banked before testosterone if any is present, and in men with Klinefelter syndrome and no sperm, surgery finds sperm in about half, for IVF with ICSI. Donor sperm and adoption are the other routes. [1], [32] See what if you want children.

Will I need TRT for life?

For primary and organic secondary hypogonadism, usually yes. For functional secondary hypogonadism, sometimes not: the EAA says testosterone may be withdrawn after weight loss or when opioids can be stopped or swapped. [22], [15] See is treatment lifelong.

Glossary

Plain explanations of the medical, lab and research terms used in this guide. Underlined terms in the text link here.

Compensated hypogonadism

Normal testosterone with a high LH, as if the pituitary is working harder to keep testosterone up. Its meaning is unclear, and it is usually watched rather than treated.

Dopamine agonist (cabergoline)

A medicine that copies the brain chemical dopamine, which normally holds prolactin down. Cabergoline is the usual choice for a prolactinoma; it lowers prolactin and shrinks the tumor.

FSH (follicle-stimulating hormone)

A pituitary hormone that acts on the cells supporting sperm production. It is high in primary hypogonadism and low or normal in secondary hypogonadism.

Functional vs organic hypogonadism

Organic hypogonadism comes from permanent damage or a genetic cause. Functional hypogonadism is a suppression, for example from obesity, opioids or illness, that may reverse when the cause is treated.

GnRH (gonadotropin-releasing hormone)

The brain signal that tells the pituitary to release LH and FSH. Gonadorelin is a medicine that copies it.

Gonadotropins

The pituitary hormones LH and FSH, and medicines that act like them, such as hCG and FSH injections, which are used to start sperm production in secondary hypogonadism.

Gynecomastia

Growth of breast tissue in men, often tender at first. It can come with high prolactin or a higher estrogen-to-testosterone balance.

Hazard ratio

A measure comparing how often an event happens over time in two groups. A hazard ratio of 1 means no difference; 0.96 means about 4% lower in the first group.

hCG (human chorionic gonadotropin)

A hormone medicine that acts like LH and tells the testes to make testosterone. It is FDA-approved for men with hypogonadotropic hypogonadism and cannot help testes that have failed.

Hematocrit

The share of the blood made up of red blood cells. Testosterone therapy can raise it, which is why it is checked.

Hypogonadotropic hypogonadism

Another name for secondary hypogonadism: low testosterone because the brain and pituitary send too little LH and FSH. It can be present from birth or start later.

Hypothalamus

A small area at the base of the brain that controls many hormones. It starts the testosterone signal chain by releasing GnRH.

ICSI (intracytoplasmic sperm injection)

An IVF technique in which a single sperm is injected directly into each egg. It lets men with very few sperm, including sperm retrieved surgically, father a child.

Kallmann syndrome

Congenital hypogonadotropic hypogonadism together with a poor or missing sense of smell. Puberty usually does not start or finish without treatment.

Karyotype

A blood test that counts and checks a person's chromosomes. It diagnoses Klinefelter syndrome (47,XXY).

Klinefelter syndrome

A chromosome difference in which a male has an extra X chromosome (47,XXY). It is the most common genetic cause of primary hypogonadism and of having no sperm.

Leydig cells

Cells in the spaces between the testicle's tubules that make testosterone when LH or hCG reaches them.

LH (luteinizing hormone)

A pituitary hormone that tells the testicles to make testosterone. It is high in primary hypogonadism, low or normal in secondary, and switched off by testosterone therapy.

Macroprolactin

A large, inactive form of prolactin bound to antibodies. It raises the prolactin reading without causing symptoms, so labs can test for it when a result does not fit.

Micro-TESE

Microdissection testicular sperm extraction: surgery under a microscope to find areas of the testicle still making sperm, used for IVF with ICSI in men with no sperm in their semen.

Odds ratio

A measure comparing the odds of an outcome in two groups. An odds ratio of 2 means roughly twice the odds; 1 means no difference.

Orchitis

Inflammation of a testicle, most often from mumps after puberty. It can shrink the testicle and reduce sperm production.

Pituitary gland

A pea-sized gland below the brain that releases LH, FSH, prolactin and other hormones.

Primary hypogonadism

Low testosterone because the testicles themselves do not work well, even though the pituitary sends plenty of LH and FSH. Also called hypergonadotropic hypogonadism.

Prolactin and prolactinoma

Prolactin is a pituitary hormone; too much of it switches off the signal to the testes. A prolactinoma is a usually benign pituitary tumor that makes prolactin.

Relative risk ratio

A measure from studies that compare several outcome groups at once, showing how much more likely one group is than the comparison group. A value of 1 means no difference.

Secondary hypogonadism

Low testosterone because the brain and pituitary send too little LH and FSH to the testicles. Also called hypogonadotropic or central hypogonadism.

SERM (selective estrogen receptor modulator)

A tablet, such as clomiphene, enclomiphene or tamoxifen, that blocks estrogen's feedback in the brain so the pituitary releases more LH and FSH.

TRT (testosterone replacement therapy)

Prescribed testosterone, by injection, gel or other forms, for men with low testosterone. It switches off the brain's LH and FSH signals.

Varicocele

Enlarged veins in the scrotum around a testicle, similar to varicose veins. It is a common finding in men being checked for infertility.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is banned at all times.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: clinical guidelines from 13 medical bodies, product labels, regulatory documents, population studies, clinic records and clinical trials. We also reviewed public online forums where men describe their own tests, diagnoses and treatment decisions.

The guide cites 127 sources, including 58 original studies in people (14 of them randomized), 14 reviews and meta-analyses, 16 clinical guidelines and consensus statements, 8 product labels, and 19 public community discussions. Each type of source answers a different question. Guidelines and labels show what clinicians are told to do. Trials and studies show what was measured. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources